Role of lamivudine in the reactivation of hepatitis B virus infection in immunodepressed patients;Papel de la lamivudina en la reactivación de la infección por el virus B en pacientes inmunodeprimidos

Revista Espanola de Enfermedades Digestivas

Volumn 95, Issue 11, 2003, Pages 799-808

  Marin E ^a   Rendon P ^a   de Diego, L ^a   Soria, Ma J ^a   Martinez Ma C ^a   Martín Herrera, Leopoldo ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

Author keywords

Chemotherapy; Hepatitis B virus; Lamivudine; Lymphoma; Transplantation

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; LAMIVUDINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; VINCRISTINE;

ADULT; ANAMNESIS; ANTIVIRAL ACTIVITY; ARTICLE; BIOCHEMISTRY; CADAVER KIDNEY; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; DOSE RESPONSE; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GRAFT REJECTION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE DEFICIENCY; KIDNEY TRANSPLANTATION; LYMPHOMA; MALE; NONHUMAN; POSTOPERATIVE PERIOD; SIDE EFFECT; TREATMENT OUTCOME; VIRUS REACTIVATION; VIRUS REPLICATION;

EID: 0348226963     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Malik AH, Lee WM. Chronic hepatitis B virus infection: treatment strategies for the next millennium. Ann Intern Med 2000; 132: 723-31.
2. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Ann Rev Immunol 1995; 13: 29-60.
3. Liang RH, Lok AS, Lai CL, Chan TK, Todd D, Chiu EK. Hepatitis B infection in patients with lymphomas. Hematol Oncol 1990; 8: 261-70.
4. Liang R, Lau G, Kwong Y.L. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol 1999; 17: 394-8.
5. Yeo W, Chan P, Zhong S, Ho W, Steinberg J, Tam J, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62: 299-307.
6. Blanpain C, Knoop C, Delforge ML, Antoine M, Peny MO, Liesnard C, et al. Reactivation of hepatitis B after transplantation in patients with pre-exixtin anti-hepatitis B surface antigen antibodies. Transplantation 1998; 66: 883-6.
7. Liu Cj, Lai MY, Lee PH, Chou NK, Chu SH, Chen PJ, et al. Lamivudine treatment for hepatitis B reactivation in AgHBs carriers after organ transplantation: A 4-year experience. J Gastroenterol Hepatol 2001; 16: 1001-8.
8. Chou CK, Wang LH, Lin HM, Chi CW. Glucocorticoid stimulates hepatitis B viral gene expression in cultured hepatoma cells. Hepatology 1992; 16: 13-8.
9. Cote PJ, Korba BE, Baldwin B, Hornbuckle WE, Tennant BC, Gerin JL. Immunosuppression with cyclosporin during the incubation period of experimental woodchuck hepatitis virus infection increases the frequency of chronic infection in adult woodchucks. J Infect Dis 1992; 166: 628-31.
10. Gong ZJ, De Meyer S, Clarysse C, Verslype C, Neyts J, De Clercq E, et al. Mycophenolic acid, an immunosuppressive agent, inhibits HBV replication in vitro. J Viral Hepat 1999; 6: 229-36.
11. Steinberg JL, Yeo W, Zhong S, Chan J, Tam J, Chan P, et al. Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/core mutations may play an important role. J Med Virol 2000; 60; 249-55.
12. Bréchot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Bréchot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult". Hepatology 2001; 34: 194-206.
13. Hu K-Q. Occult hepatitis B virus infection and its clinical implications. J Viral Hepat 2002: 9; 243-57.
14. Bisharat N, Segol O, Raz R, Flatau E. Isolated hepatitis B surface antibody as a sole marker for past HBV infection. J Infect 1998; 37: 201-2.
15. Chung H-T, Lai CH-L, Lok A. Pathogenic role of hepatitis B virus in hepatitis B surface antigen-negative descompesated cirrhosis. Hepatology 1995; 22: 25-9.
16. Iwai K, Tashima M, Itoh M, Okazahi T, Yamamoto K, Ohno H, et al. Fulminant hepatitis B following bone marrow transplantation in an HbsAg-negative, HbsAb-positive recipient; reactivation of dormant virus during the immunosuppressive period. Bone Marrow Transplantation 2000; 25; 105-8.
17. Endo T, Sawada K, Fujimoto K, Yamamoto S, Takashima H, Haseyama Y, et al. Reactivation of hepatitis B virus after autologous peripheral blood stem cell transplantation in patients with positive hepatitis B surface antibodies. [Article in Japanese]. Rinsho Ketsueki 2000; 41: 322-8. (Abstract).
18. Ishiga K, Kawatani T, Suou T, Tajima F, Omura H, Idobe Y, et al. Fulminant hepatitis type B after chemotherapy in a serologically negative hepatitis B virus carrier with acute myelogenous leukemia. Int J Hematol 2001; 73: 115-8.
19. Lok ASF, Liang RHS, Chiu EKW, Wong K-L, Chan T-K, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Repot of a prospective study. Gastroenterology 1991; 100: 182-8.
20. Nevens F, Main J, Honkoop P, Tyrell DL, Barber J, Sullivan MT, et al. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology 1997; 113: 1258-63.
21. Kanai N, Hasegawa K, Ogawa M, Naritomi T, Hayashi N. Lamivudine treatment for acute exacerbation of hepatitis B in patients undergoing immunosuppressive therapy. Hepatol Res 2002; 22: 223-30.
22. Yao G, Wang B, Cui Z, Yao J, Zeng M. A randomised double-blind placebo-controlled study of lamivudine in the treatment of patients with chronic hepatitis B virus infection. Chin Med J (Engl) 1999; 112: 387-391. (Abstract)
23. Kawai Y, Ikegaya S, Hata M, Kawahito M, Imamura S, Yoshida A, et al. Successful lamivudine therapy for post-chemotherapeutic fulminant hepatitis B in a hepatitis virus carrier with non-Hodgkin's lymphoma: case report and review of the literature. Ann Hematol 2001; 80: 482-4.
24. Rostaing L, Henry S, Cisterne JM, Duffaut M, Icart J, Durand D. Efficacy and safety of lamivudine on replication of recurrent hepatitis B after cadaveric renal transplantation. Transplantation 1997; 64: 1624-7.
25. Da Silva LC, Rebello JR, Sitnik R, Pinto Da Fonseca LE, Carrilho FJ. Efficacy and tolerability of long-term therapy using lamivudine doses for the treatment of chronic hepatitis B. J Gastroenterol 2001; 36: 476-85.
26. Buti M, Cotrina M, Jardi R, de Castro EC, Rodríguez-Frías F, Sánchez-Ávila F, et al. Two years of lamivudine therapy in anti-Hbe-positive patients with chronic hepatitis B. J Viral Hepat 2001; 8: 270-5. (Abstract)
27. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001; 33: 1527-32.
28. Fischer KP, Gutfreund KS, Tyrrell DL. Lamivudine resistance in hepatitis B: mechanisms and clinical implications. Drug Resist Updat 2001; 4: 118-28. (Abstract)
29. Silvestri F, Ermacora A, Sperotto A, Patriarca F, Zaja F, Damiani D, et al. Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation. Br J Haematol 2000; 108; 394-6.
30. Xunrong L, Yan AW, Liang R, Lau GKK. Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy-pathogenesis and management. Rev Med Virol 2001; 11: 287-99.
31. Seksik P, Nahon S, Lesgourgues B, Cadranel J-F, Mairaud de Serre N, Lenoble M, et al. Efficacité du traitement par lamivudine chez deux malades ayant eu une réactivation sévère d'une hépatite B induite par Iárrêt d'un traitement chimiothérapique. Gastroenterol Clin Biol 2000; 24: 671-4.
32. Endo T, Sakai T, Fujimoto K, Yamamoto S, Takashima H, Haseyama Y, et al. A possible role for lamivudine as prophylaxis against hepatitis B reactivation in carriers of hepatitis B who undergo chemotherapy and autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplantation 2001; 27: 433-6.
33. Cainelli F, Longhi MS, Concia E, Vento S. Failure of lamivudine therapy for chemotherapy-induced reactivation of hepatitis B. Am J Gastroenterol 2001; 96: 1651-2.